[go: up one dir, main page]

CR8352A - Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos - Google Patents

Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos

Info

Publication number
CR8352A
CR8352A CR8352A CR8352A CR8352A CR 8352 A CR8352 A CR 8352A CR 8352 A CR8352 A CR 8352A CR 8352 A CR8352 A CR 8352A CR 8352 A CR8352 A CR 8352A
Authority
CR
Costa Rica
Prior art keywords
acute coronary
procedures
prevention
treatment
coronary syndromes
Prior art date
Application number
CR8352A
Other languages
English (en)
Inventor
L Bisgaier Charles
V Rodrigueza Wendi
D Lalwani Narendra
Hartman Daniel
Johansson Jan
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CR8352A publication Critical patent/CR8352A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion proporciona nuevas formulaciones y procedimientos para tratar o prevenir sindromes coronarios agudos. En una realizacion preferida, las formulaciones son dosis unitarias unicas que tienen un pH, osmolalidad y pureza especificadas. En un procedimiento preferido, la formualcion se administra semanalmente, mensualmente o anualmente en un intervalo de dosis aproximadamente 1 mg/kg a aproximadamente 100 mg/kg por administracion.
CR8352A 2003-10-20 2006-04-20 Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos CR8352A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51311603P 2003-10-20 2003-10-20
US51701603P 2003-11-03 2003-11-03
US57112904P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
CR8352A true CR8352A (es) 2007-03-02

Family

ID=34557347

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8352A CR8352A (es) 2003-10-20 2006-04-20 Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos

Country Status (23)

Country Link
US (2) US7435717B2 (es)
EP (1) EP1677597B1 (es)
JP (1) JP2007509157A (es)
KR (3) KR20060080227A (es)
AR (1) AR046126A1 (es)
AU (2) AU2004284932A1 (es)
CA (1) CA2542726C (es)
CO (1) CO5690611A2 (es)
CR (1) CR8352A (es)
EA (1) EA010134B1 (es)
EC (1) ECSP066516A (es)
ES (1) ES2449719T3 (es)
GE (1) GEP20094601B (es)
IL (1) IL174301A (es)
MA (1) MA28102A1 (es)
MX (1) MXPA06004362A (es)
NO (1) NO339456B1 (es)
NZ (1) NZ545939A (es)
OA (1) OA13272A (es)
PA (1) PA8615301A1 (es)
PE (1) PE20050438A1 (es)
RS (1) RS20060273A (es)
WO (1) WO2005041866A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US8500795B2 (en) 1999-08-09 2013-08-06 Cardiokinetix, Inc. Retrievable devices for improving cardiac function
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
NZ532217A (en) * 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
CA2615975C (en) * 2005-07-22 2012-11-27 The Procter & Gamble Company Compositions for reducing the incidence of drug induced arrhythmia
WO2007130724A2 (en) * 2006-02-06 2007-11-15 Northwind Ventures Systems and methods for volume reduction
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
BRPI0708494A2 (pt) * 2006-03-03 2011-05-31 Activbiotics Pharma Llc tratamento de doença aterosclerótica
DE102007006663A1 (de) * 2007-02-10 2008-08-21 Lts Lohmann Therapie-Systeme Ag Transport von Arzneistoffen über die Blut-Hirn-Schranke mittels Apolipoproteinen
US8044021B2 (en) 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
PL2398502T3 (pl) * 2009-02-18 2016-03-31 Cormatrix Cardiovascular Inc Kompozycje i sposoby do zapobiegania zaburzeniu rytmu serca
EP2401587A2 (en) 2009-02-27 2012-01-04 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
EP2405933A1 (en) * 2009-03-13 2012-01-18 Medtronic, Inc Method of treating heart failure
EP2932994B1 (en) 2009-07-30 2017-11-08 Tandem Diabetes Care, Inc. New o-ring seal, and delivery mechanism and portable infusion pump system related thereto
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
EP2493417B1 (en) 2009-10-26 2017-06-21 Cardiokinetix, Inc. Ventricular volume reduction
ES2617977T3 (es) 2010-06-30 2017-06-20 Csl Limited Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma
CA2807433A1 (en) 2010-08-30 2012-03-08 Martin Bader Method for producing a lipid particle, the lipid particle itself and its use
KR20130117760A (ko) 2010-08-30 2013-10-28 에프. 호프만-라 로슈 아게 테트라넥틴-아포지단백질 a-i 입자의 제조 방법, 이에 의해 제조된 지질 입자 및 이의 용도
US9187550B2 (en) 2010-08-30 2015-11-17 Hoffman—La Roche Inc. Tetranectin-apolipoprotein A-I, lipid particles containing it and its use
CN103443123B (zh) * 2011-02-07 2020-05-29 塞勒尼斯医疗控股公司 脂蛋白复合物及其制备和用途
AU2012249324B2 (en) * 2011-04-27 2016-10-06 Ionis Pharmaceuticals, Inc. Modulation of apolipoprotein CIII (ApoCIII) expression
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
KR20140054115A (ko) 2011-08-25 2014-05-08 에프. 호프만-라 로슈 아게 단축 테트라넥틴-아포지단백질 a-i 융합 단백질, 그를 함유하는 지질 입자 및 그의 용도
US20140378376A1 (en) * 2011-12-21 2014-12-25 Csl Limited Dosage Regime for Apolipoprotein Formulations
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2014011908A1 (en) 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
JP6549554B2 (ja) 2013-03-15 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア コレステロール流出を刺激する、減少した毒性を有するペプチド
US10335535B2 (en) * 2013-10-31 2019-07-02 Novo Nordisk A/S Injection device with a needle cannula
CN106852115A (zh) 2014-09-28 2017-06-13 卡迪欧凯尼迪克斯公司 用于治疗心功能不全的装置
US10668015B2 (en) * 2015-01-20 2020-06-02 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
MX379081B (es) * 2015-08-25 2025-03-11 Novo Nordisk As Dispositivo médico de inyección con cámara limpiadora.
DE102018107407A1 (de) 2017-03-28 2018-10-04 Edwards Lifesciences Corporation Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
NZ532217A (en) 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
EP1556413A4 (en) * 2002-05-17 2009-07-08 Esperion Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC REPERFUSION
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia

Also Published As

Publication number Publication date
US7435717B2 (en) 2008-10-14
NO339456B1 (no) 2016-12-12
EA200600548A1 (ru) 2006-10-27
EA010134B1 (ru) 2008-06-30
RS20060273A (sr) 2008-09-29
EP1677597A2 (en) 2006-07-12
NZ545939A (en) 2008-08-29
MA28102A1 (fr) 2006-08-01
ECSP066516A (es) 2006-11-24
PE20050438A1 (es) 2005-06-14
CA2542726A1 (en) 2005-05-12
JP2007509157A (ja) 2007-04-12
IL174301A (en) 2013-09-30
WO2005041866A2 (en) 2005-05-12
WO2005041866A3 (en) 2006-05-18
AU2011202014B2 (en) 2012-06-14
OA13272A (en) 2007-01-31
US20080293633A1 (en) 2008-11-27
NO20062110L (no) 2006-07-18
GEP20094601B (en) 2009-02-10
AU2011202014A1 (en) 2011-05-26
KR20060080227A (ko) 2006-07-07
EP1677597A4 (en) 2011-08-24
ES2449719T3 (es) 2014-03-20
KR20070110561A (ko) 2007-11-19
US20050142180A1 (en) 2005-06-30
KR20100101710A (ko) 2010-09-17
AU2004284932A1 (en) 2005-05-12
MXPA06004362A (es) 2006-09-04
PA8615301A1 (es) 2005-09-28
CO5690611A2 (es) 2006-10-31
HK1093869A1 (en) 2007-03-16
CA2542726C (en) 2012-05-15
EP1677597B1 (en) 2014-01-08
AR046126A1 (es) 2005-11-23
IL174301A0 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
CR8352A (es) Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
ES2153338T1 (es) Dosificacion mejorada de dosis multiples de medicamentos.
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
WO2005065646A3 (en) Novel drug compositions and dosage forms
BRPI0415007A (pt) método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
AR020001A1 (es) COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ATE269056T1 (de) Hochwirksame dihydroergotaminhaltige arzneizusammensetzungen
PT1207756E (pt) Utilizacao de espinosade ou de uma formulacao que compreende espinosade
CA2503810A1 (en) Therapeutic agent for fibromyalgia
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
BR0315593A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
CO5540323A2 (es) Administracion oral de hormona paratiroides y calcitonina
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
RU2007104774A (ru) Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)